+1-888-308-5802     
News Contact Us

Canada’s Canopy Growth acquires C3 Cannabinoid Compound Company

Author : Paroma Bhattacharya | Published Date : 2019-05-03 
  • C3 Cannabinoid Company is one of the foremost distributor and manufacturer of dronabinol, a registered pharmaceutical medicine in Denmark, Switzerland, Austria, and Germany.
     
  • C3 would be an excellent addition to the Canopy’s European infrastructure including a robust sales and marketing setup already serving healthcare practitioners and pharmacies.

The Canada-based Canopy Growth Corporation has reportedly announced that it has successfully acquired C3 Cannabinoid Compound Company – a Bionorica SE-founded German firm. As per trusted sources, the acquisition deal would bring together the world’s foremost full-spectrum medical cannabis offerings along with single cannabinoid medicines.

Reportedly, the all cash-deal is being valued at about CDN 342.9 million. Industry experts claim that the deal would expand Canopy Growth Corporation’s reach in the European nations with prescription medicines and would allow it to access a wealth of intellectual property that the company has created over the last 2 decades via research and development into natural and synthetic cannabis medical products.

The Co-CEO and Chairman of Canopy Growth Corporation, Bruce Linton was reportedly quoted saying that the new acquisition would enable the company to offer more options to doctors across Europe and speed up the pace of commercial sales, drive forward new innovations, and increase the company’s economic footprint on the continent.

The goal of Canopy Growth Corporation is to build upon the extraordinary reputation of C3 and decades of success as the company moves to a unique range of medical cannabis therapies which would allow physicians globally to treat their patients in a better manner, Linton further added.

Reportedly, the chief medicinal offering of C3 is dronabinol – a pure chemical compound with uniform concentrations of tetrahydrocannabinol (THC). It is available in Germany, Denmark, and Austria for nausea and vomiting refractory to traditional treatment in cancer pain, oncology and palliative care. For the record, THC is one of the active ingredients found in cannabis plants and is responsible for various pharmacological effects.

 

Source Credit:  https://finance.yahoo.com/news/canopy-growth-acquires-germanys-c3-110000225.html

https://www.cannabisbusinesstimes.com/article/canopy-growth-acquires-c3-cannabinoid-compound-company/

About Author

Paroma Bhattacharya

Paroma Bhattacharya

Paroma Bhattacharya, having completed her post-graduation in Journalism and Mass Communication, started her career in writing with resourceful and informative content development across diverse fields. Having dealt in myriad topics ranging from business to real estate, she now pens down articles for fractovia.org and other portals. She can be contacted at- [email protected] | https://twitter.com/paromab1

Related News

US-based software firm MathWorks undertakes expansion in Hyderabad

Published Date: 2019-07-18         Author: Paroma Bhattacharya

MathWorks, a US-based computer software company that specializes in mathematical computing software has recently announced expansion in Hyderabad. The organization has shifted its operations to a facility, which is 3 times bigger than its previous office in Hyderabad, cite sources. For the record... Read More

Swiggy eying to raise $500 million through South Korean funding

Published Date: 2019-07-15         Author: Paroma Bhattacharya

Swiggy, the online food delivery app is planning to raise funds for its next phase of expansion. The company is reportedly in talks with South Korean venture capital funds, including STIC Investments, Korea Investment Partners, Neoplux & Mirae Asset Management, to bag $500 million in a funding r... Read More

Interbit to upgrade InterbitTM platform, signs contract with Xinova

Published Date: 2019-07-13         Author: Paroma Bhattacharya

Interbit Ltd., a technology platform provider, recently announced progress of its proprietary technology platform, InterbitTM. The company revealed that it would focus solely on the development of the proprietary platform & is testing its performance to allow support of commercial opportunities ... Read More

© 2019 Fractovia. All Rights Reserved